McKesson Corporation (MCK) Analyst/Investor Day Transcript

McKesson Corporation's 2025 Investor Day underscored its successful strategy of disciplined portfolio management and strategic investments in high-growth healthcare segments, resulting in robust financial performance. The company announced plans to separate its Medical-Surgical segment by H2 2027 through an IPO and subsequent spin-off/split-off to enhance strategic focus. McKesson updated its FY26 adjusted EPS guidance to $38.05-$38.55 (15-17% growth) and raised its long-term adjusted EPS growth target to 13-16%, driven by strong momentum in its North American Pharmaceutical, Oncology & Multi-specialty (bolstered by acquisitions like Florida Cancer and PRISM), and Prescription Technology Solutions segments, all capitalizing on evolving market dynamics and technological advancements.

Analysis

McKesson's 2025 Investor Day detailed a successful strategic pivot, reshaping the company into a more focused, higher-growth healthcare services leader. Management reinforced its disciplined portfolio management, highlighted by the planned tax-free separation of the Medical-Surgical Solutions business, which is targeted for completion by the second half of calendar 2027. This move, combined with a new segment structure, enhances transparency and sharpens focus on the core growth pillars: Oncology & Multispecialty and Prescription Technology Solutions (PTS), which now represent over 33% of adjusted operating profit (AOP). The company's financial execution is strong, evidenced by an upgraded fiscal 2026 adjusted EPS guidance to $38.05-$38.55, representing 15-17% YoY growth, and an increased long-term adjusted EPS growth target of 13-16%. The Oncology & Multispecialty segment is a key driver, with FY26 AOP growth guided at 49-53%, fueled by organic expansion and strategic acquisitions like Florida Cancer Specialists and PRISM Vision. The PTS segment also shows robust momentum, with its FY26 AOP growth outlook raised to 11-15%, benefiting from strong demand for its access and affordability solutions, including for GLP-1 therapies which constitute 11% of segment revenue. The foundational North American Pharmaceutical business continues to generate significant cash flow and operating leverage, while expanding its specialty distribution capabilities, which now account for approximately $90 billion in revenue and have grown at an 18% CAGR since fiscal 2021. The capital allocation strategy remains a core strength, with a stated commitment to organic investment, strategic M&A, and significant shareholder returns, including a 13% dividend CAGR since fiscal 2021 and a projected $16.6 billion in share repurchases between FY21-FY26.

Key Decisions for Investors

• Investors should recognize the ongoing business mix shift towards the higher-margin, high-growth Oncology & Multispecialty and Prescription Technology Solutions segments, which now underpin the newly raised long-term adjusted EPS growth target of 13-16%.
• The planned separation of the Medical-Surgical segment by H2 2027 represents a significant potential catalyst for value creation, creating a more streamlined enterprise focused on its most profitable platforms and enabling more precise capital deployment.
• Consider the company's strong track record of shareholder returns, which is supported by robust free cash flow, a consistently growing dividend, and an aggressive, value-accretive share repurchase program that has significantly reduced shares outstanding.
• Monitor execution within the Oncology & Multispecialty platform, as its ability to successfully integrate recent acquisitions like Florida Cancer and PRISM and continue its organic growth in providers and clinical trial services is critical to achieving its ambitious 13-16% long-term AOP growth target.